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CONCLUSIONS: Patients with schizophrenia treated
with either risperidone or olanzapine achieved better drug
therapy outcomes after the formulary expansion. The
higher cost of drug therapy was largely offset by reduc-
tions in the use of other services.
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OBJECTIVES: 1) To understand why naltrexone, a med-
ication approved by the FDA to treat alcoholism, has not
diffused widely and 2) to demonstrate the use of stated
preference techniques for predicting physicians’ demand
for medications with various characteristics.
METHODS: Survey of 1372 physicians specializing in
substance abuse treatment (65% response rate). Ques-
tions about the use of naltrexone and perceptions of nal-
trexone. Stated preference questions in which physicians
are asked to select medications for treating alcoholism
based on hypothetical medication characteristics. Com-
bined actual and stated preference data are used to
examine the accuracy of stated preference data for 
forecasting demand for new medications.
RESULTS: Only 2% of physicians had never heard of 
naltrexone, 11% had heard of naltrexone but were not
conﬁdent in their knowledge about its indications. The
mean percent of alcoholism patients prescribed naltrex-
one was 13%. 37% of physicians did not prescribe nal-
trexone to any of their patients. When physicians were
asked the main reason that they did not prescribe nal-
trexone to more patients the following reasons were
given: 19% said “patients refused to take or comply with
medications;” 17% said “patients could not afford 
medications;” 11% said “small effect size relative to 
side-effects;” 10% said “patients were not in a formal
treatment program.” Other analyses will also be pre-
sented that examine ratings of efﬁcacy, side-effects, and
compliance with naltrexone relative to other more widely
used medications. Physicians demand curves and market-
share for alcoholism medications are estimated using
stated preference data.
CONCLUSIONS: Although naltrexone is familiar to
most specialists in substance abuse it is still not widely
prescribed. A variety of reasons explain why naltrexone
is not more widely prescribed. Efforts to increase its use
will require efforts focused on a number of areas, includ-
ing educating physicians and increased availability of the
medication outside of formal treatment programs.
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OBJECTIVE: Previous research evaluating labor 
market outcomes in schizophrenia has focused mainly on
patients’ earnings, providing an overall economic impact.
Two studies exploring employment participation in 
schizophrenic patients found that “negative” symptoms
(e.g., apathy and social withdrawal) are stronger predic-
tors of employment than “positive” symptoms (halluci-
nations and delusions), however, these studies were based
on a static model. In the present study, we used a dynamic
employment decision model to examine the impact of
schizophrenia symptoms on employment outcomes.
METHODS: The decision model was empirically 
estimated using patients with a DSM-III diagnosis of
schizophrenia from the Epidemiologic Catchment Area
Study data, 1980–1985 (n = 133). The variables of 
interest (presence of only positive symptoms, only nega-
tive symptoms, or both) were measured as dichotomous
variables. Ordinary least squares regression was used to
determine the effect of symptoms on months of unem-
ployment. The dependent variable was also broken into
discrete outcomes (continuous employment, discontinu-
ous employment, and unemployment) and an ordered
probit model was estimated. Both models controlled for
demographics, family social support, additional income,
and illness severity.
RESULTS: Most patients experienced both positive and
negative symptoms (82%); no patients experienced only
negative symptoms. Positive symptoms only and both
positive and negative symptoms were signiﬁcantly associ-
ated with more months of unemployment (14.2 and 13.6
months, respectively) compared with an average of 20
months in patients with no symptoms (p < 0.001); no 
difference was detected in the coefﬁcient estimates
between the positive symptoms only group and the posi-
tive and negative symptoms group. Results of the ordered
probit model were not signiﬁcant.
CONCLUSION: In this study, the presence of symptoms
in schizophrenic patients increased the duration of unem-
ployment by more than a year. This suggests that greater
symptom control, possibly through aggressive pharma-
cotherapy, may lead to increased employment rates
among schizophrenic patients, making them more 
productive members of society.
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OBJECTIVES: To compare medication treatment pat-
terns for patients who initiated on olanzapine (OLZ)
versus risperidone (RIS).
METHODS: Retrospective analysis of a large, geographi-
cally diverse claims database of insured individuals 
identiﬁed 670 enrollees who: (1) were diagnosed with
schizophrenia; (2) initiated on OLZ (n = 423) or RIS (n
= 247) monotherapy, and (3) had no use of OLZ or RIS
in one year prior-initiation. Multivariate analyses were
used to compare the OLZ and RIS groups with respect
to treatment duration and likelihood of receiving 
medication for at least 80% of days during the one-year
post-initiation, likelihood of switching between study
drugs, and likelihood of receiving concomitant treatment
for Parkinsonian symptoms. Regressions controlled for
demographics, comorbidities, and previous medication
use patterns.
RESULTS: Compared to RIS (mean dose = 3.32mg/day),
patients treated with OLZ (mean dose = 10.45mg/day)
experienced a 29.4% increase in treatment duration (162
days vs. 213 days; p < 0.0001), a higher probability of
receiving medication for at least 80% of days (Odds Ratio
= 2.057, p = 0.0002), a decrease in the probability of 
concomitant use of anti-Parkinsonian medications (Odds
Ratio = 0.639; p = 0.0284). Patients who initiated on
OLZ were less likely to switch to RIS than vice versa
(Odds Ratio = 0.275; p < 0.0001).
CONCLUSIONS: Compared to RIS, patients treated
with OLZ experienced a longer duration of therapy, an
increased likelihood of receiving 80% of days of therapy,
a decreased likelihood of concomitant use of anti-
Parkinsonian agents, and a lower probability of switch-
ing among medications of interest.
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Studies have shown that systemic absorption of oph-
thalmic beta-blockers (OBBs) can potentially cause severe
systemic side effects.
OBJECTIVES: To evaluate the use of OBBs among
patients with a contraindication or precaution against its
use.
METHODS: We conducted a retrospective analysis of
pharmacy and medical claims data from a West Coast
health plan. Patients receiving a prescription for oph-
thalmic betaxolol, carteolol, levobunolol, metipranolol,
or timolol between 7/1/98 and 6/30/00 were included in
this study. Study cohorts were identiﬁed based upon the
ﬁrst OBB agent received and were followed for 180 days.
Patients receiving prescriptions for different OBBs that
were more than 180 days apart were categorized as
having two episodes of care. OBBs are contraindicated 
in patients with sinus bradycardia/persistent severe 
bradycardia, asthma, COPD, and greater than ﬁrst degree
heart block. OBBs have precautions against use in 
patients having diabetes mellitus, congestive heart 
failure, Raynaud’s phenomenon, or using oral beta-
blockers. OBB use was deﬁned as inappropriate if used
simultaneously with oral beta-blockers, within 15 days of
heart block diagnosis, or within 6 months of the other 
conditions.
RESULTS: A total of 9,094 unique patients contributed
9,294 episodes of care. The percentage of patients with a
contraindication or precaution against OBB use, respec-
tively, was 12.7% and 20.9% (betaxolol: 19.9% with
contraindication, 22.7% with precaution; carteolol:
9.7%, 20.9%; levobunolol: 13.0%, 21.5%; metipra-
nolol: 9.2%, 21.5%; timolol: 10.7%, 20.3%). Overall,
29.6% of patients had at least one contraindication or
precaution against OBB use, and 7.6% had multiple 
contraindications and/or precautions.
CONCLUSION: Nearly three out of ten patients who
received an OBB had a contraindication or precaution
against its use. Further research is needed to determine
the incidence of clinically signiﬁcant adverse effects from
prescribing OBBs in these patient populations, and to
identify alternative glaucoma medications that may be
more appropriate for these patients.
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OBJECTIVES: Current treatments for non-melanoma
skin cancer (NMSC) can be problematic when lesions are
in cosmetically sensitive sites. Patients may also be unsuit-
able for standard therapies for other reasons. Cosmetic
procedures are therefore common. Methyl aminolevuli-
nate (Metvix) photodynamic therapy (MAL PDT) has
comparable lesion response rates and superior cosmetic
outcomes in such patients. The aim of this study was to
estimate the mean total costs of treatment to the UK
